Merck Sharp + Dohme Corp.

Dohme Ltd.

Merck Sharp

Philip Stephen Jackson

Janusz Jozef Kulagowski

Christopher John Swain

Brian John Williams

Neil Roy Curtis

Jason Matthew Elliott

Gregory John Hollingworth

Timothy Harrison

Raymond Baker

Nadia Melanie Rupniak

Eileen Mary Seward

Eileen May Seward

The present invention provides methods for the treatment of major depressive disorders comprising oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.

Use of NK-1 receptor antagonists for treating major depressive disorders

The present invention provides methods for the treatment or prevention of cognitive disorders which comprises oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.

Use of NK-1 receptor antagonists for treating cognitive disorders

The present invention is directed to substituted spiro-azacyclic derivatives of the formula (I):

Spiro-azacyclic derivatives and their use as therapeutic agents

The present invention provides methods for the treatment or prevention of major depressive disorder with anxiety without concomitant therapy with other anti-depressant or anti-anxiety agents which comprises oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.

The present invention provides a method for the treatment or prevention of schizophrenic disorders using an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.

Use of NK-1 receptors antagonists for treating schizophrenic disorders

The present invention provides methods for the treatment or prevention of amnestic disorders which comprises oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist.

Use of NK-1 receptor antagonists for treating amnestic disorders

The present invention provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of stress disorders without concomitant therapy with other anti-stress agents, methods of treatment using such a NK-1 receptor antagonist and pharmaceutical compositions comprising it.

Use of NK-1 receptor antagonists for treating stress disorders

Spiro-piperidine derivatives and their use as therapeutic agents

The present invention provides methods for the treatment or prevention of bipolar disorder without concomitant therapy with other antidepressant or anti-anxiety agents which comprises oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.

Use of NK-1 receptor antagonists for treating bipolar disorders

The present invention provides a method for the treatment or prevention of sexual dysfunctions which comprises oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such an NK-1 receptor antagonist.

Use of NK-1 receptor antagonists for treating sexual dysfunctions

The present invention provides a method for the treatment or prevention of movement disorders using an orally active, long acting, CNS-penetrant NK-1 antagonist and pharmaceutical compositions comprising such an antagonist.

Use of NK-1 receptor antagonists for treating movement disorders

The present invention provides a method for the treatment or prevention of substance use disorders using an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.

Growing community of inventors

Harlow, United Kingdom

Philip Stephen Jackson